PROLIFIC: Prognostic Lung Fibrosis Consortium supports researchers developing and validating blood-protein biomarker assays to advance pulmonary fibrosis drug development and help tailor treatment.
Funder: Pulmonary Fibrosis Foundation
Due Dates: Membership inquiries welcome (no deadline specified)
Funding Amounts: Consortium research funded by members; individual award amounts not specified
Summary: PROLIFIC brings organizations together to develop and validate blood-protein biomarkers for pulmonary fibrosis drug development and tailored treatment.
Key Information: Participation is through consortium membership inquiries from organizations.
The Prognostic Lung Fibrosis Consortium (PROLIFIC), launched by the Pulmonary Fibrosis Foundation and Bristol Myers Squibb, brings pharmaceutical companies and foundations together to advance pulmonary fibrosis research and drug development. It promotes cooperation among competitors to create a company-agnostic assay for drug development, with a long-term goal of identifying biomarkers that predict which patients will benefit most from particular treatments.
Members focus on 12 blood-protein biomarkers across epithelial damage, fibrosis, inflammation, and thrombosis. Using samples from the PFF Registry and its biorepository, researchers develop and validate assays to study disease prognosis and early indicators of drug activity. The work aims to support exploratory, prognostic, and predictive biomarker use in clinical trials and ultimately help physicians tailor therapies.